Sofinnova Partners
在场
Sofinnova Partners 在 2 个国家有直接业务。
高管
查看带有其 60 名主要高管的组织结构图
Sofinnova Partners 搜索最多的简介
- Antoine Papiernik, Managing Partner and Chairman of the Board
- Mary McCarthy, Partner, Industrial Biotech Strategy
- Stéphanie Huiban, Head of Information Systems
高管在Sofinnova Partners变化
- Anta Gkelou 曾任 Principal, Capital Strategy, 现升职为 Partner, Capital Strategy (新闻发布的2024四月24号).
- Guillaume Baxter 曾任 Principal, Industrial Biotech Strategy, 现升职为 Partner, Industrial Biotech Strategy (新闻发布的2024四月24号).
- Andrew Weiss已作为Venture Partner加入公司 (新闻发布的2023十二月22号).
创建提醒
跟踪 Sofinnova Partners 的高管变动
基金
Sofinnova Partners 拥有 1,475 家竞争者，其中包括 Lloyds Development Capital (联合王国)、BlackRock (美国(美洲)) 和 WindRose Health Investors (美国(美洲))。
Popular M&A news in 基金
- HMC Capital 已收购 StratCap (公布2024二月28号).
- Thomvest Ventures 刚刚宣布为 250 筹款数百万美元。 (公布2024一月17号).
- BlackRock has announced the acquisition of Global Infrastructure Partners (公布2024一月15号).
基金 行业的其他推荐联系人
- Valor Equity Partners 企业 Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer
- Vanguard 企业 Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024)
- Caisse de Dépôt et Placement du Québec 企业 Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra
消息
Sofinnova Partners 的最新新闻稿
- NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial — Sofinnova Partners
- Moon Surgical expands to gynecological surgery — Sofinnova Partners
- Sensorion announces a €15 Million financing, extending cash runway until the end of 2025 — Sofinnova Partners
- Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first in class treatments and transform cancer into a curable disease — Sofinnova Partners
- Asceneuron joins critical path for Alzheimer’s Disease Consortium — Sofinnova Partners
- Moon Surgical's Maestro System powered by NVIDIA Holoscan paves the way to next-generation laparoscopy, with over 200 patients treated — Sofinnova Partners
- Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy — Sofinnova Partners
- Amolyt Pharma enters into definitive agreement to be acquired by AstraZeneca — Sofinnova Partners
- Signature of a partnership agreement with Kiro — Sofinnova Partners
- Sofinnova Partners portfolio company Amolyt Pharma to be acquired by AstraZeneca — Sofinnova Partners
- View more press releases Close
通过电子邮件
